Key points are not available for this paper at this time.
Investigations of long-term outcomes have been instrumental in designing safer and more effective contemporary therapies for pediatric hematological malignancies. Despite the significant therapeutic changes that have occurred over the last five decades, therapy modifications largely represent refinements of treatment protocols using agents and modalities that have been available for more than 30 years. This review summarizes major trends in the evolution of treatment of pediatric hematological malignancies since 1960 to support the relevance of the study of late effects of historical therapeutic approaches to the design and evaluation of contemporary treatment protocols and the follow-up of present-day survivors.
Building similarity graph...
Analyzing shared references across papers
Loading...
Melissa M. Hudson
Cardio-Oncology
Joseph P. Neglia
University of Minnesota
William G. Woods
Emory University
Pediatric Blood & Cancer
University of Minnesota
Emory University
St. Jude Children's Research Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Hudson et al. (Fri,) studied this question.
synapsesocial.com/papers/6a166abfa8d6c30f746240b3 — DOI: https://doi.org/10.1002/pbc.23385
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: